Cnb

The dose which the patient gets through the mouthpiece of the device is 180 mcg.

Cnb contains 200 doses of finely powdered beclomethasone dipropionate mixed in a small quantity of lactose. The amount of drug received by the patient (180 mcg/dose) corresponds to that from 2 puffs of the freon-based beclomethasone inhalation aerosol with a metered dose of 100 mcg/dose. The dose to be inhaled is released from the container by pressing the device between the thumb and the forefinger. This is followed by inhalation through the device. As a result, beclomethasone dipropionate particles are transferred to their target, the lungs. Use of the Cnb does not require coordination of actuation of the dose and inhalation.

Beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. BECONE is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic rhinitis. It is also indicated for the prevention of recurrence of nasal polyps following surgical removal.

Beclomethasone is a steroid. It prevents the release of substances in the body that cause inflammation.

Beclomethasone nasal is used to treat nasal symptoms such as congestion, sneezing, and runny nose caused by seasonal or year-round allergies. The Cnb brand of this medication is also used to keep nasal polyps from coming back after surgery to remove them.

Beclomethasone may also be used for purposes not listed in this medication guide.

Management of Chronic Asthma: Adults and Children >12 years: 100-400 mcg twice daily. Maximum: 1000 mcg twice daily.

Children (5-12 years): 100-200 mcg twice daily. Maximum: 200-400 mcg twice daily.

Prophylaxis of Asthma: Adults and Children >12 years: 50-200 mcg twice daily. Increase if necessary to maximum 400 mcg twice daily.

Children (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses.

When patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.

Therapy in New Patients: Mild Asthma: 50-100 mcg twice daily.

Moderate Asthma: 100-200 mcg twice daily.

Severe Asthma: 200-400 mcg twice daily.

When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially Cnb 100 mcg puff should be prescribed for Cnb (CFC) or budesonide 200-250 mcg; fluticasone propionate 100 mcg.

When switching a patient with poorly-controlled asthma from another corticosteroid inhaler, initially Cnb 100 mcg puff should be prescribed for Cnb (CFC) or budesonide or fluticasone propionate 100 mcg. The dose of Cnb should be adjusted to response.

Use in the elderly or patients with hepatic or renal impairment: There are no special dosage recommendations for use in the elderly or in patients with hepatic or renal impairment.

Hypersensitivity to any of the ingredients of this preparation contraindicates its use. Status asthmaticus, acute episodes of asthma.

Cnb is used to treat runny nose, swelling and itching of the nose due to allergy (allergic rhinitis), hay fever and ulcerative colitis. Cnb reduces inflammation, swelling and irritation in nose and helps to relieve itching, sneezing and blocked or runny nose. It is also used in asthma and ulcerative colitis.

See also:
What other drugs will affect Cnb?

No drug interactions have been described with inhaled beclomethasone.

See also:
What are the possible side effects of Cnb?

The most commonly noted side effects associated with inhaled beclomethasone are mild cough or wheezing due to chemical irritation; these effects may be minimized by using an inhaled bronchodilator (e.g., albuterol or Ventolin) prior to the beclomethasone.

Oral candidiasis or thrush, a fungal infection of the mouth and throat, can occur in between 1 in 20 and 1 in 8 persons who use beclomethasone. The risk of thrush is greater with higher doses, but the risk in children is lower than in adults. Hoarseness may occur in as few as 1 in 20 or as many as 1 in 2 persons and is due to chemical irritation. A spacer device that can be attached to the inhaler and washing out the mouth with water following each use of beclomethasone reduces the amount of beclomethasone in the mouth and throat and reduces the risk of thrush and hoarseness.

Higher doses of inhaled beclomethasone (more than 1000 mcg/day) may result in more absorption into the body. This may decrease bone formation and increase bone breakdown (resorption), resulting in weak bones and a risk of fractures. Even higher doses (more than 1500 mcg/day in adults and 400 mcg/day in children) may suppress the adrenal glands and impair their ability to make natural glucocorticoid. People with such suppression (which can be identified by testing) need increased amounts of glucocorticoid orally or by the intravenous route during periods of high physical stress since higher amounts of glucocorticoids are needed by the body to fight physical stress. Patients receiving beclomethasone may develop easy bruising if enough beclomethasone is absorbed into the body from the lungs.